The current financial score of Evaxion Biotech A/S is 7.14. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 22.81%.
The current valuation score of Evaxion Biotech A/S is 9.78. Its current P/E ratio is -15.77, which is -99.22% below the recent high of -0.12 and -36.93% above the recent low of -21.59.
The current earnings forecast score of Evaxion Biotech A/S is 8.00. The average price target is 11.25, with a high of 16.00 and a low of 9.00.
The current price momentum score of Evaxion Biotech A/S is 3.82. Currently, the stock price is trading between the resistance level at 3.49 and the support level at 2.99, making it suitable for range-bound swing trading.
The current institutional shareholding score of Evaxion Biotech A/S is 3.00. The latest institutional shareholding proportion is 3.88%, representing a quarter-over-quarter increase of 48.82%.
No risk assessment score is currently available for Evaxion Biotech A/S. The Biotechnology & Medical Research industry's average is 3.94. The company's beta value is 0.26. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.